Hemostatic Abnormalities in Multiple Myeloma Patients.
Gogia A et al. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):127-130.

Incidence of Second Primary Malignancies after Autologous Transplantion for Multiple Myeloma in the Era of Novel Agents.
Sahebi F et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30021-1. doi: 10.1016/j.bbmt.2018.01.006. [Epub ahead of print].

Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation.
Tendas A et al. Clin Lymphoma Myeloma Leuk. 2017 Dec 24. pii: S2152-2650(17)31875-X. doi: 10.1016/j.clml.2017.12.001. [Epub ahead of print].

Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.
Chen Y et al. Ann Hematol. 2018 Jan 15. doi: 10.1007/s00277-018-3238-4. [Epub ahead of print].

Postsurgical pyoderma gangrenosum after an autologous stem cell transplantation for multiple myeloma.
Bittencourt MCB et al. BMJ Case Rep. 2018 Jan 5;2018. pii: bcr-2017-222286. doi: 10.1136/bcr-2017-222286.

Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
Waxman AJ et al. JAMA Oncol. 2017 Dec 28:e174519. doi: 10.1001/jamaoncol.2017.4519. [Epub ahead of print].

Identifying a combined biomarker for bisphosphonate-related osteonecrosis of the jaw.
Kim KY et al. Clin Implant Dent Relat Res. 2017 Dec 20. doi: 10.1111/cid.12569. [Epub ahead of print].